THE FUTURE OF
BLOOD STEM CELL
THERAPIES

OVERVIEW

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

Our platform technology for generating self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. As the industry’s first off-the-shelf offering, Garuda’s technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells.

LEADERSHIP

Garuda was founded and is supported by experts in blood stem cell and bone marrow transplants as well as leaders with expertise in bringing transformative medicines to patients.

Leadership Team

Dhvanit Shah, Ph.D.

Founder, President, & CEO

James Desiderio, Ph.D.

Chief Regulatory Officer

Giorgia Scapin, Ph.D.

Senior Vice President & Head, Research and Development

Roger Sawhney, M.D.

Chief Financial Officer

David DiGiusto, Ph.D.

Chief Technology Officer

The Founders

Dhvanit Shah, Ph.D.

Founder, President, & CEO

Former Principal Faculty,
Harvard Stem Cell Institute

Former Associate Member,
Broad Institute of MIT and Harvard

David Scadden

David Scadden, M.D.

Co-Founder

Co-Director,
Harvard Stem Cell Institute

Gerald and Darlene Jordan
Professor of Medicine, Harvard University

Sean Morrison

Sean Morrison, Ph.D.

Co-Founder

Investigator,
Howard Hughes Medical Institute

Director, Children’s Research Institute,
UT Southwestern Medical Center

Board of Directors

Dhvanit Shah, Ph.D.

Founder, President, and CEO
Garuda Therapeutics, Inc.

Eric Aguiar, M.D.

Partner
Aisling Capital

Carl Gordon, Ph.D., CFA

Managing Partner
OrbiMed

Daniel Janse, Ph.D.

Director
Northpond Ventures

Rahul Singhvi, Sc.D.

Co-Founder and CEO
National Resilience, Inc.

Laurence Reid, Ph.D.

CEO
Decibel Therapeutics

Raymond-Kelleher

Raymond J. Kelleher, M.D., Ph.D.

Managing Director at Cormorant Asset Management

Scientific Advisory Board

David Scadden

David Scadden, M.D.

Co-Director, Harvard Stem Cell Institute

Gerald and Darlene Jordan Professor of Medicine, Harvard University

Sean Morrison

Sean Morrison, Ph.D.

Investigator, Howard Hughes Medical Institute

Founder & Director, Children’s Research Institute at UT Southwestern Medical Center

Robert Negrin, M.D.

Professor of Medicine, Stanford University

Former Chief of the Division of Blood and Marrow Transplantation, Stanford University

JeromeRitz

Jerome Ritz, M.D.

Executive Director, Connell and O’Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute

Professor of Medicine, Harvard Medical School

vandenbrink

Marcel van den Brink, M.D., Ph.D.

Head, Division of Hematologic Malignancies &
Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center

maillard_ivan2 (1)

Ivan Maillard, M.D., Ph.D.

Professor of Hematology-Oncology, University of Pennsylvania School of Medicine

photo-Katja-G-Weinacht

Katja G. Weinacht, M.D., Ph.D.

Assistant Professor of Pediatrics, Stanford University School of Medicine

photo-John-E-Wagner

John E. Wagner, M.D.

Distinguished McKnight Professor of Pediatrics, University of Minnesota

photo-Giorgia-Scapin

Giorgia Scapin, Ph.D.

Harvard Medical School

News

February
7
2023

Fly like an eagle: Garuda brings in a $62M series B

The science that led Garuda Therapeutics Inc. to a $62 million series B financing was a combination of hard work, luck and serendipity, according to co-founder and CEO Dhvanit Shah.

At the Harvard Stem Cell Institute, Shah and his fellow researchers found that endothelial cells go through significant modifications before becoming hematopoietic stem cells. That simple discovery, as Shah told BioWorld, brought on research leading to the possibility that patients would not need a marrow donor before receiving a stem cell treatment. read more →

February
7
2023

Stem cell startup raises $62M amid ‘difficult economic environment’

Fifteen months after launching with $72 million and a mission to treat 70 different diseases with stem cell-based drugs, Garuda Therapeutics has raised another $62 million and now says it’s looking at 120 potential target diseases.

Garuda announced the new funding on Tuesday morning. Backing the Series B round are lead investors Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management and Aisling Capital, with participation from Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments and others. read more →

February
7
2023

Blood stem cell therapy maker Garuda nabs $62M

Garuda Therapeutics brought in $62 million via a Series B to take its off-the-shelf cell therapies into the clinic next year.

The Boston-area biotech wants to rid the need for blood stem cell transplants and instead give patients self-renewing blood stem cells. The proceeds, which add to a $72 million Series A from September 2021, will bankroll two lead programs in hematological and oncology indications, Garuda said Tuesday morning. read more →

February
7
2023

Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform

CAMBRIDGE, Mass. – February 7, 2023 – -Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital, along with participation from Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments, and other elite investors and individuals. read more →

January
5
2023

Garuda Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. – January 5, 2023 – -Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30pm PT / 7:30pm ET. read more →

November
15
2022

Garuda Therapeutics Announces Appointment of David DiGiusto, Ph.D., as Chief Technology Officer

CAMBRIDGE, Mass. – November 15, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of David DiGiusto, Ph.D., as Chief Technology Officer. Dr. DiGiusto most recently served as CTO and SVP Stem Cells and Regenerative Medicine at National Resilience Inc., a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. read more →

September
7
2022

Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer

CAMBRIDGE, Mass. – September 7, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of Roger Sawhney, M.D., as Chief Financial Officer. Dr. Sawhney previously served as Chief Financial Officer and Chief Business Officer at Omega Therapeutics, a pioneer in mRNA-based therapeutics for precision gene modulation. read more →

March
15
2022

Garuda Therapeutics Announces Appointment of James Desiderio as Chief Regulatory Officer

CAMBRIDGE, Mass. – March 15, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of James Desiderio, Ph.D. as Chief Regulatory Officer. Dr. Desiderio previously served as Senior Vice President of Regulatory Affairs and Quality at Acceleron Pharma. read more →

January
6
2022

Garuda Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. – January 6, 2022 – Garuda Therapeutics (Garuda), today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 (Tuesday) at 5:30 pm EST. read more →

January
5
2022

Garuda Therapeutics Announces Appointment of Laurence Reid to Board of Directors

CAMBRIDGE, Mass. – January 5, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of Laurence Reid, Ph.D. to its board of directors… read more →

November
8
2021

Could new stem cell technology eliminate need for donors’ cells?

National Institutes of Health (NIH) features the promise of Garuda Therapeutics technology

“Look at that! Life!” said Deidra Flowers-Williams, a sickle cell disease patient, as she held up a tube with stem cells donated by her sister, Tanisha Flowers. It was just minutes before doctors at the NIH Clinical Center… read more →

September
23
2021

Garuda Therapeutics Launches with $72 Million Series A Financing

First off-the-shelf, long-term durable blood stem cell platform has potential to cure more than 70 diseases, eliminate dependency on donor or patient cells
CAMBRIDGE, Mass. – September 23, 2021 – Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed $72 million Series A financing … read more →

September
23
2021

Harvard professor launches stem cell startup with $72M

One platform, 70 diseases and $72 million — these underpin the launch of Garuda Therapeutics, a new stem cell startup founded by Harvard professor Dhvanit Shah… read more →

September
23
2021

Garuda thinks it has cracked the code to off-the-shelf stem cell transplants—and investors are betting $72M to find out

We know blood stem cell transplants are potential cures for serious diseases. The problem is, patients need cells from immune-compatible donors, creating a supply bottleneck that constrains use in some areas and blocks expansion into new diseases. Garuda Therapeutics thinks it may have… read more →

September
23
2021

Looking to make donor cells obsolete, an ex-Harvard researcher gets off-the-shelf stem cell biotech off the ground

A stem cell researcher who spent time at the Harvard Stem Cell Institute, the Broad Institute and Brigham and Women’s Hospital launched a new biotech Thursday, and he’s attracted significant blue-chip investment to get things up and running…. read more →

Join Us

We are seeking team members who share our passion for science, work ethic, and sense of urgency to improve patients’ lives.